In patients who had revascularization after an acute MI and had a preserved EF, long-term beta-blocker use showed no benefit compared with no beta-blockers, in REDUCE-AMI.
For an all-comer population with any impairment of LV function, an interarterial shunt device missed the primary endpoint in RELIEVE-HF, but benefit was seen with LVEF less than 40%.
A new study suggested indexed left ventricular systolic volume may predict benefit of beta blocker withdrawal in patients with heart failure with preserved ejection fraction.
The Barostim neuromodulation system is now indicated in NYHA class III or class II HF despite guideline-directed medical therapies, with LVEF ≤ 35% and NT-proBNP < 1600 pg/mL.